This is second HBV compound ABUS has killed off in the past few months—in Oct 2019 ABUS terminated AB-506, a capsid inhibitor, due to a safety problem (#msg-151513575).
What’s left in ABUS’ pipeline? ABS-452, an injected RNA destabilizer, is in phase-1; and ABS-836 (the successor to the terminated AB-506), a capsid inhibitor*, is in preclinical development with phase-1 anticipated in 2021.
ABUS is down “only” 6% on today’s PR because it has been known for over a year that AB-452 had a safety issue.
-- *ENTA (#msg-153696410) and ASMB (#msg-148672065) are also developing an HBV capsid inhibitor (a/k/a “core” inhibitor or CpAM).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.